1[1]Williams KA,Muehlberg SM,Lewis RF,Coster DJ. How successful is corneal transplantation-a report from the Australian corneal graft register[J].Eye 1995;9(pt2): 219-227.
2[2]Rocha G, Deschenes J, Rowsey JJ. The immunology of corneal graft rejection[J]. Critl Rev Immunol 1998;18(4): 305-325.
3[3]Bellgrau D,Gold D,Selawry H,Moore J,Franzusoff A,Duke RC. A role for CD95 ligand in preventing graft rejection[J]. Nature 1995;377(6550): 630-632.
4[4]Yamagami S,Kawashima H,Tsuru T,Yamagami H,Kayagaki N,Yagita H,et al. Role of fas-fas ligand interactions in the immunorejection of allogeneic mouse corneal transplants[J]. Transplantation 1997;64(8): 1107-1111.
6[6]Wilson SE,Li Q,Weng J, Barry Lane PA,Jester JV, Liang Q,et al. The Fas/Fas ligand system and other modulators of apoptosis in the cornea[J]. Invest Ophthalmol Vis Sci 1996;37(8): 1582-1592.
7[7]Li XY, De Marco BM, Mayhew ES, Niederkorn JY. Aqueous humor-borne factor upregulates Bcl-2 expression in corneal endothelial cells[J]. Curr Eye Res 1998;17(10):970-978.
8[8]Griffith TS, Ferguson TA. The role of FasL-induced apoptosis in immune privilege[J]. Immunol Today 1997;18(5): 240-244.
9[9]Krams SM, Egawa M, Quinn MB, Martinez OM. Apoptosis as a mechanism of cell death in a rat model of liver allograft rejection[J]. Transplantation Proc 1995;27(1):466-467.
10[10]Suzuki I, Fink PJ. Maximal proliferation of cytotoxic T lymphocytes requires reverse signaling through Fas ligand[J]. J Exp Med 1998;187(1): 123-128.
